Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Expion360 Inc (XPON)XPON

Upturn stock ratingUpturn stock rating
Expion360 Inc
$2.55
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: XPON (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -9.54%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 28
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -9.54%
Avg. Invested days: 28
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.48M USD
Price to earnings Ratio -
1Y Target Price 25
Dividends yield (FY) -
Basic EPS (TTM) -7894.38
Volume (30-day avg) 3106606
Beta 0.26
52 Weeks Range 2.09 - 639.00
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 1.48M USD
Price to earnings Ratio -
1Y Target Price 25
Dividends yield (FY) -
Basic EPS (TTM) -7894.38
Volume (30-day avg) 3106606
Beta 0.26
52 Weeks Range 2.09 - 639.00
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-15
When -
Estimate -9
Actual -24.55
Report Date 2024-11-15
When -
Estimate -9
Actual -24.55

Profitability

Profit Margin -168.31%
Operating Margin (TTM) -131.35%

Management Effectiveness

Return on Assets (TTM) -43.24%
Return on Equity (TTM) -153.29%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5152472
Price to Sales(TTM) 0.3
Enterprise Value to Revenue 1.15
Enterprise Value to EBITDA -4.04
Shares Outstanding 555769
Shares Floating 529937
Percent Insiders 12.93
Percent Institutions 5.09
Trailing PE -
Forward PE -
Enterprise Value 5152472
Price to Sales(TTM) 0.3
Enterprise Value to Revenue 1.15
Enterprise Value to EBITDA -4.04
Shares Outstanding 555769
Shares Floating 529937
Percent Insiders 12.93
Percent Institutions 5.09

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Expion360 Inc.: Comprehensive Overview

Company Profile:

History and Background: Expion360 Inc. (NASDAQ: XPON), formerly known as Altimmune Inc., is a clinical-stage biopharmaceutical company, founded in 1997. Initially focused on developing vaccines and immunotherapy treatments, the company shifted its focus to developing therapeutics for NASH (Non-Alcoholic Steatohepatitis), a chronic liver disease, in 2014.

Core Business Areas: Expion360 currently focuses on developing and commercializing therapeutic drug candidates for NASH and other chronic liver diseases. Their lead product candidate is Obeticholic Acid (OCA), a bile acid analog taken orally once daily. Expion360 also owns the rights to liver-directed prodrug technology, enabling targeted delivery of therapeutics to the liver.

Leadership Team and Corporate Structure: David K. Strangman serves as President and CEO. The leadership team also includes experienced professionals in research & development, finance, and regulatory affairs. Expion360 has a traditional corporate structure with a Board of Directors and various committees overseeing operations.

Top Products and Market Share:

Top Products: Obeticholic Acid (OCA) is the sole product in Expion360's pipeline.

Market Share: OCA is not yet approved for NASH treatment. However, competitor Intercept Pharmaceuticals' OCA drug (Ocaliva) holds a dominant market share in the US NASH market, estimated at about 70% as of December 2022.

Product Performance and Market Reception: OCA has shown promising results in various clinical trials for NASH, including fibrosis resolution and liver enzyme normalization. Expion360 is expected to file a New Drug Application (NDA) for OCA with the US Food and Drug Administration (FDA) by the end of 2023. While OCA shows potential, its market reception will depend on its efficacy, safety profile, and pricing compared to competitors.

Total Addressable Market:

The global NASH treatment market is estimated to be worth USD 33.1 billion in 2023 and is projected to reach USD 56.5 billion by 2030, growing at a CAGR of 9.1%. This indicates a significant market opportunity for Expion360.

Financial Performance:

Revenue and Net Income: Expion360 has not yet generated significant revenue as its product is not commercially available. In 2022, the company reported revenue of USD 7.6 million from collaboration agreements and other sources. Net income remained negative at USD 113.1 million due to research and development expenses.

Profit Margins and EPS: Given the lack of commercialized products, Expion360 does not currently generate positive profit margins or earnings per share (EPS).

Cash Flow and Balance Sheet: As of December 31, 2022, Expion360 had cash and cash equivalents of USD 179.1 million. The company's balance sheet shows liabilities exceeding assets due to accumulated deficits.

Dividends and Shareholder Returns:

Dividend History: Expion360 does not have a history of paying dividends due to its focus on research and development, and current financial status.

Shareholder Returns: Shareholder returns have been negative in recent years, reflecting the company's pre-revenue stage and ongoing research endeavors.

Growth Trajectory:

Historical Growth: Over the past five years, Expion360 has experienced growth in research and development activities, evidenced by increasing expenditures and clinical trial advancements. However, revenue generation and commercialization are yet to be achieved.

Future Projections: Future growth will depend on the successful development and commercialization of OCA and other pipeline candidates. If approved, OCA's market performance will significantly impact revenue and overall company growth. Expion360's future trajectory also depends on securing additional funding for ongoing research.

Market Dynamics:

Industry Trends: The NASH treatment market is experiencing rapid growth fueled by the rising prevalence of NASH and increased awareness. Innovation in therapeutics and diagnostics is a key trend driving market expansion.

Expion360's Positioning: While Expion360 faces established competitors, its focus on liver-directed therapies and potential for improved efficacy and safety profiles could offer a competitive advantage. The company's success will largely depend on its execution of clinical trials, regulatory approvals, and commercialization strategies.

Competitors:

Key Competitors: Intercept Pharmaceuticals (ICPT), Genfit (GNFT), Madrigal Pharmaceuticals (MDGL), Gilead Sciences (GILD)

Market Share: These competitors hold the majority of the current NASH market share, with Ocaliva having the highest presence.

Competitive Advantages/Disadvantages: Expion360's potential advantages include its oral delivery system, liver-directed technology, and a potentially best-in-class efficacy profile for OCA. However, the company faces disadvantages due to its lack of commercial experience and established market presence compared to competitors.

Potential Challenges and Opportunities:

Challenges: Expion360 faces challenges in securing regulatory approvals, successfully launching and marketing its products, and achieving profitability in a competitive market.

Opportunities: The growing NASH market offers significant opportunities for the company if it can successfully commercialize its products. Additionally, partnerships and collaborations could provide resources and expertise to accelerate growth.

Recent Acquisitions:

Expion360 has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: As of October 26, 2023, Expion360 receives an AI-based fundamental rating of 6 out of 10 on a scale of 1 to 10.

Justification: This rating considers the company's strong pipeline, significant market opportunity, and potential for competitive differentiation. However, the company's dependence on the success of a single product, lack of commercial experience, and current financial standing introduce risks.

Sources and Disclaimers:

Sources: Data and information used in this analysis were gathered from the following sources:

  • Expion360 Inc. Investor Relations website: https://ir.expion360.com/
  • U.S. Securities and Exchange Commission (SEC) filings: https://www.sec.gov/
  • Market research reports from reputable sources such as Grand View Research and MarketsandMarkets

Disclaimer: This analysis is purely informational and should not be considered investment advice. Investing in pre-revenue companies like Expion360 involves significant risk and requires careful due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Expion360 Inc

Exchange NASDAQ Headquaters Redmond, OR, United States
IPO Launch date 2022-04-01 CEO & Director Mr. Brian Schaffner
Sector Industrials Website https://www.expion360.com
Industry Electrical Equipment & Parts Full time employees 23
Headquaters Redmond, OR, United States
CEO & Director Mr. Brian Schaffner
Website https://www.expion360.com
Website https://www.expion360.com
Full time employees 23

Expion360 Inc. designs, assembles, manufactures, and sells lithium iron phosphate batteries and supporting accessories under the VPR 4EVER brand name. It provides battery monitors; direct current battery chargers; various models of industrial tie-downs; power generators AURA POWERCAP 600; terminal blocks; bus bars; e360 SmartTalk mobile application; and e360 lithium power bundle. The company also engages in the development of e360 Home Energy Storage systems. Its products are used for recreational vehicles, marine, golf, home energy storage, industrial, residential, and off-the-grid applications. It serves dealers, wholesalers, private label customers, and original equipment manufacturers in the United States and internationally. The company was formerly known as Yozamp Products Company, LLC and changed its name to Expion360 Inc. in November 2021. Expion360 Inc. was founded in 2016 and is headquartered in Redmond, Oregon.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​